Enlivex Announces a new publication “Apoptotic cell therapy for cytokine storm associated with acute severe sepsis” in Cell Death & Disease, a Nature Research Journal
20 juil. 2020 08h20 HE
|
Enlivex Therapeutics Ltd
- Data show a 90% decrease in mortality with AllocetraTM treatment in a murine cecal ligation and puncture severe sepsis model Nes Ziona, Israel, July 20, 2020 (GLOBE NEWSWIRE) -- Enlivex...
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
18 juin 2020 08h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, June 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of...
Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
01 juin 2020 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate...
Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting
28 mai 2020 08h30 HE
|
Enlivex Therapeutics Ltd
- Exploratory endpoint analyses demonstrated Allocetra’s potential therapeutic effect in resolving cytokine storms in patients with heterogenous pathologies Nes Ziona, Israel, May 28, 2020 ...
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
07 mai 2020 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center...
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
13 avr. 2020 08h25 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority (IIA)...
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
18 mars 2020 08h00 HE
|
Enlivex Therapeutics Ltd
– Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly...
Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment
09 mars 2020 08h13 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, March 09, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236)...
Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering
05 mars 2020 08h15 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced...
Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea
03 mars 2020 08h53 HE
|
Enlivex Therapeutics Ltd
Regarding Submission of Proposal to the Korean Authorities for Potential Use of AllocetraTM as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU Nes-Ziona, Israel,...